Medigene's Asian deal helps fund PhIII breast cancer trial with EndoTAG-1
This article was originally published in Scrip
Executive Summary
Medigene has struck the first licensing deal for its pipeline candidate for triple-negative breast cancer (TNBC) EndoTAG-1, granting exclusive co-development and commercialisation rights in Asia, Australia and New Zealand to Taiwan's SynCore Biotechnology.